FDA Clears Self-Administered Lupus Therapy - Top-Institutions - MDSpire

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

  • By

  • Kathryn Wighton

  • April 28, 2026

  • 2 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Rheumatology
    • Immunology
    • Autoimmune Diseases

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Autoimmune Diseases
    • Clinical Trials

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Rheumatology
    • Immunology
    • Autoimmune Disease Research

  • #4

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Rheumatology
    • Autoimmune Diseases
    • Clinical Research

  • #5

    University of Michigan
    University of Michigan

    Ann Arbor, MI

    Key Differentiators

    • Rheumatology
    • Autoimmune Diseases
    • Clinical Trials

Original Source(s)

FDA Clears Self-Administered Lupus Therapy

  • by Kathryn Wighton

  • April 28, 2026

Related Content

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

Reversibility of calcinosis in anti-NXP2-positive refractory dermatomyositis treated with TNF-α blockade: a brief report